THISX Performance — T. Rowe Price Health Sciences Fund, Inc., I Class
Data updated: 2026-08-27
THISX returned +7.34% year to date and +30.21% over one year to Jun 2026. Annualised returns are +9.60% over 3 years and +3.91% over 5 years. The fund trailed its Health Care Equity category average: $100 invested three years ago grew to $132, against $138 for the category, and to $130 over one year, against $137. Volatility over the past three years was 15.25% a year. In the 12 months to Jun 2026 the fund lost a net $1.0B, and assets reached $11.95B.
THISX Growth of $100
What $100 invested in T. Rowe Price Health Sciences Fund, Inc. grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | THISX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $130 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $132 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $121 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $190 | $182 |
THISX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +7.34% |
| 1 year | +30.21% |
| 3 years (annualised) | +9.60% |
| 5 years (annualised) | +3.91% |
THISX Annual Returns
Calendar-year total returns of T. Rowe Price Health Sciences Fund, Inc., compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +7.34% |
| 2025 | +17.89% |
| 2024 | +1.93% |
| 2023 | +3.22% |
| 2022 | −12.08% |
| 2021 | +13.40% |
| 2020 | +30.28% |
| 2019 (Jul–Dec) | +9.92% |
THISX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.0% | +0.7% | −5.9% | +1.6% | +3.5% | +8.8% | — | — | — | — | — | — |
| 2025 | +6.2% | −1.8% | −4.1% | −0.1% | −6.5% | +4.0% | −1.3% | +4.2% | +2.2% | +7.8% | +9.1% | −1.8% |
| 2024 | +2.0% | +4.1% | +1.7% | −5.0% | +2.3% | +2.9% | +2.7% | +5.2% | −1.9% | −5.0% | +1.5% | −7.6% |
| 2023 | +0.6% | −4.7% | +1.9% | +3.6% | −2.9% | +2.9% | −0.1% | −1.5% | −3.9% | −3.9% | +5.6% | +6.3% |
| 2022 | −12.4% | −0.4% | +4.8% | −8.6% | −0.9% | −0.5% | +5.6% | −3.1% | −4.2% | +7.7% | +4.2% | −3.0% |
| 2021 | +2.4% | −1.8% | −0.8% | +5.0% | −0.9% | +5.6% | +2.0% | +4.2% | −4.7% | +4.2% | −4.9% | +3.0% |
| 2020 | −2.7% | −4.3% | −7.0% | +13.9% | +7.6% | +0.8% | +3.3% | +1.8% | +1.6% | −1.1% | +10.0% | +4.7% |
| 2019 | — | — | — | — | — | — | −1.3% | −2.9% | −3.7% | +6.6% | +8.6% | +2.9% |
THISX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 15.25%
- 3-year Sharpe ratio: 0.33 (vs 4.5% risk-free rate)
- Best month: +9.09% (Nov 2025)
- Worst month: −7.61% (Dec 2024)
THISX Fund Flows
Monthly money in and out of T. Rowe Price Health Sciences Fund, Inc., from SEC Form N-PORT.
- 12-month net flow: −$1.0B
- 12-month gross sales (incl. reinvestments): $2.5B
- Sales ÷ redemptions: 0.71×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $64.8M | $218.2M | −$153.5M |
| May 2026 | $42.3M | $206.4M | −$164.1M |
| Apr 2026 | $552.4M | $699.1M | −$146.7M |
| Mar 2026 | $45.6M | $198.6M | −$153.0M |
| Feb 2026 | $128.5M | $275.3M | −$146.8M |
| Jan 2026 | $62.4M | $216.4M | −$154.0M |
| Dec 2025 | $1.4B | $306.5M | $1.0B |
| Nov 2025 | $95.6M | $224.2M | −$128.6M |
| Oct 2025 | $44.6M | $244.6M | −$199.9M |
| Sep 2025 | $44.2M | $251.9M | −$207.8M |
| Aug 2025 | $52.4M | $352.8M | −$300.4M |
| Jul 2025 | $45.1M | $359.0M | −$313.9M |
THISX Assets Under Management
Net assets of T. Rowe Price Health Sciences Fund, Inc. by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $11.95B |
| 2026-03-31 | $10.89B |
| 2025-12-31 | $12.08B |
| 2025-09-30 | $11.01B |
| 2025-06-30 | $11.30B |
| 2025-03-31 | $12.32B |
| 2024-12-31 | $13.03B |
| 2024-09-30 | $15.45B |
| 2024-06-30 | $14.91B |
| 2024-03-31 | $15.41B |
| 2023-12-31 | $14.72B |
| 2023-09-30 | $14.39B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.